BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5(10): 528-540 [PMID: 24179612 DOI: 10.4254/wjh.v5.i10.528] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 113] [Article Influence: 17.1] [Reference Citation Analysis]
Number Citing Articles
1 Jia B, Yu D, Yu G, Cheng Y, Wang Y, Yi X, Li X, Wang Y. Naringenin improve hepatitis C virus infection induced insulin resistance by increase PTEN expression via p53-dependent manner. Biomed Pharmacother 2018;103:746-54. [PMID: 29684853 DOI: 10.1016/j.biopha.2018.04.110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 28.0] [Reference Citation Analysis]
3 Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853-861. [PMID: 27476823 DOI: 10.1016/j.cmi.2016.07.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 14.6] [Reference Citation Analysis]
4 Büsch K, Waldenström J, Lagging M, Aleman S, Weiland O, Kövamees J, Duberg A, Söderholm J. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scandinavian Journal of Gastroenterology 2017;52:61-8. [DOI: 10.1080/00365521.2016.1228119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
5 de Camargo AR, Tenório JR, Martins F, Grando LJ, Corrêa EBD, Trierveiler M, Ortega KL. Subset of CD8+ and FOXP3 + T cells in lichen planus associated with chronic hepatitis C infection. Oral Dis 2019;25:1100-6. [PMID: 30801844 DOI: 10.1111/odi.13069] [Reference Citation Analysis]
6 Peng C, Wang H, Zhang WJ, Jie SH, Tong QX, Lu MJ, Yang DL. Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cells. World J Gastroenterol 2016;22:4354-61. [PMID: 27158204 DOI: 10.3748/wjg.v22.i17.4354] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Đorđević V, Stanković Đorđević D, Kocić B, Dinić M, Sokolović D, Pešić Stanković J. The Impact of Hepatitis C Virus Genotypes on Oxidative Stress Markers and Catalase Activity. Oxid Med Cell Longev 2021;2021:6676057. [PMID: 33708335 DOI: 10.1155/2021/6676057] [Reference Citation Analysis]
8 Malikova AZ, Shcherbakova AS, Konduktorov KA, Zemskaya AS, Dalina AA, Popenko VI, Leonova OG, Morozov AV, Kurochkin NN, Smirnova OA, Kochetkov SN, Kozlov MV. Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors. Int J Mol Sci 2021;22:4559. [PMID: 33925399 DOI: 10.3390/ijms22094559] [Reference Citation Analysis]
9 Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG 3rd, Tate JP, Re VL 3rd, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. J Gen Intern Med 2020;35:2025-34. [PMID: 32342483 DOI: 10.1007/s11606-020-05782-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Singaravelu R, Russell RS, Tyrrell DL, Pezacki JP. Hepatitis C virus and microRNAs: miRed in a host of possibilities. Curr Opin Virol. 2014;7:1-10. [PMID: 24721496 DOI: 10.1016/j.coviro.2014.03.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
11 Zampino R, Florio A, Coppola N, Cirillo G, Macera M, Marrone A, Adinolfi LE, Del Giudice EM. PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. Int J Cardiol. 2014;172:291-292. [PMID: 24461483 DOI: 10.1016/j.ijcard.2013.12.231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol. 2014;52:445-451. [PMID: 24871972 DOI: 10.1007/s12275-014-4267-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
13 Zhou P, Huang G, Zhao Y, Zhong D, Xu Z, Zeng Y, Zhang Y, Li S, He F. MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cell Signal. 2014;26:1347-1354. [PMID: 24631531 DOI: 10.1016/j.cellsig.2014.02.020] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
14 Barokar J, McCutchan A, Deutsch R, Tang B, Cherner M, Bharti AR. Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction. J Neurovirol 2019;25:792-9. [PMID: 31281947 DOI: 10.1007/s13365-019-00767-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Shmeleva EV, Colucci F. Maternal natural killer cells at the intersection between reproduction and mucosal immunity. Mucosal Immunol 2021;14:991-1005. [PMID: 33903735 DOI: 10.1038/s41385-020-00374-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yu JS, Chen WC, Tseng CK, Lin CK, Hsu YC, Chen YH, Lee JC. Sulforaphane Suppresses Hepatitis C Virus Replication by Up-Regulating Heme Oxygenase-1 Expression through PI3K/Nrf2 Pathway. PLoS One 2016;11:e0152236. [PMID: 27023634 DOI: 10.1371/journal.pone.0152236] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
17 Mapoure NY, Budzi MN, Eloumou SAFB, Malongue A, Okalla C, Luma HN. Neurological manifestations in chronic hepatitis C patients receiving care in a reference hospital in sub-Saharan Africa: A cross-sectional study. PLoS One. 2018;13:e0192406. [PMID: 29513678 DOI: 10.1371/journal.pone.0192406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, Delarocque‐astagneau E, Larrey D, Bourlière M, Petrov‐sanchez V, Simony M, Pol S, Fontaine H, Carrieri P; the ANRS/AFEF Hepather study group. Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C‐infected patients (ANRS CO22 Hepather cohort). J Viral Hepat 2020;27:1473-83. [DOI: 10.1111/jvh.13380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
19 Chen WC, Tseng CK, Chen BH, Lin CK, Lee JC. Grape Seed Extract Attenuates Hepatitis C Virus Replication and Virus-Induced Inflammation. Front Pharmacol 2016;7:490. [PMID: 28066241 DOI: 10.3389/fphar.2016.00490] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
20 Lin WY, Lin MS, Weng YH, Yeh TH, Lin YS, Fong PY, Wu YR, Lu CS, Chen RS, Huang YZ. Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. JAMA Neurol 2019;76:1019-27. [PMID: 31168563 DOI: 10.1001/jamaneurol.2019.1368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
21 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
22 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int Suppl (2011) 2018;8:91-165. [PMID: 30675443 DOI: 10.1016/j.kisu.2018.06.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 20.3] [Reference Citation Analysis]
23 Vepa A, Bae JP, Ahmed F, Pareek M, Khunti K. COVID-19 and ethnicity: A novel pathophysiological role for inflammation. Diabetes Metab Syndr 2020;14:1043-51. [PMID: 32640416 DOI: 10.1016/j.dsx.2020.06.056] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
24 Badawi A, Di Giuseppe G, Arora P. Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017). PLoS One 2018;13:e0208839. [PMID: 30540839 DOI: 10.1371/journal.pone.0208839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Zhang Y, El-Far M, Dupuy FP, Abdel-Hakeem MS, He Z, Procopio FA, Shi Y, Haddad EK, Ancuta P, Sekaly RP. HCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral Responses. Sci Rep. 2016;6:29447. [PMID: 27385120 DOI: 10.1038/srep29447] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
26 Akhter A, Said A. Cutaneous manifestations of viral hepatitis. Curr Infect Dis Rep 2015;17:452. [PMID: 25809574 DOI: 10.1007/s11908-014-0452-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Chan ST, Ou JJ. Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response. Viruses. 2017;9. [PMID: 28805674 DOI: 10.3390/v9080224] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
28 Fayed HM, Mahmoud HS, Elaiw Mohamed Ali A. The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. Clin Exp Gastroenterol 2020;13:53-63. [PMID: 32110084 DOI: 10.2147/CEG.S229689] [Reference Citation Analysis]
29 Oriolo G, Egmond E, Mariño Z, Cavero M, Navines R, Zamarrenho L, Solà R, Pujol J, Bargallo N, Forns X, Martin-Santos R. Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. Aliment Pharmacol Ther 2018;47:1238-52. [PMID: 29536563 DOI: 10.1111/apt.14594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Katsi V, Felekos I, Skevofilax S, Aggeli C, Tousoulis D, Stefanadis C, Kallikazaros I. Cardiovascular Disease and Hepatitis C Virus Infection: An Irrelevant Statement or a Hot Relationship? Cardiology in Review 2015;23:11-7. [DOI: 10.1097/crd.0000000000000031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
31 Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. Infect Dis Ther 2018;7:473-84. [PMID: 30368684 DOI: 10.1007/s40121-018-0218-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
33 Xu Q, Liu M, Liu Q, Wang W, Du Y, Yin H. The inhibition of LPS-induced inflammation in RAW264.7 macrophages via the PI3K/Akt pathway by highly N-acetylated chitooligosaccharide. Carbohydr Polym 2017;174:1138-43. [PMID: 28821038 DOI: 10.1016/j.carbpol.2017.07.051] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
34 Bedimo R, Maalouf NM, Lo Re V 3rd. Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS 2016;11:285-93. [PMID: 26890206 DOI: 10.1097/COH.0000000000000259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
35 Ruzicka DJ, Tetsuka J, Fujimoto G, Kanto T. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infect Dis 2018;18:237. [PMID: 29793436 DOI: 10.1186/s12879-018-3148-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 Kostadinova L, Shive CL, Anthony DD. Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation. Cancers (Basel) 2019;11:E1867. [PMID: 31769428 DOI: 10.3390/cancers11121867] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
37 Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med 2021;112:188-200. [PMID: 33205641 DOI: 10.23736/S0026-4806.20.07129-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ambrosino P, Lupoli R, Di Minno A, Tarantino L, Spadarella G, Tarantino P, Nasto A, Celentano A, Di Minno MN. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis. Int J Cardiol. 2016;221:746-754. [PMID: 27428315 DOI: 10.1016/j.ijcard.2016.06.337] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
39 Fortini I, Arouca EMG, Tengam FM, Nitrini R. Chronic HCV infection and neuropsychiatric dysfunction. eNeurologicalSci 2019;17:100206. [PMID: 31656863 DOI: 10.1016/j.ensci.2019.100206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Shalom-Elazari H, Zazrin-Greenspon H, Shaked H, Chill JH. Global fold and backbone dynamics of the hepatitis C virus E2 glycoprotein transmembrane domain determined by NMR. Biochim Biophys Acta 2014;1838:2919-28. [PMID: 25109935 DOI: 10.1016/j.bbamem.2014.07.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Huang QT, Huang Q, Zhong M, Wei SS, Luo W, Li F, Yu YH. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat 2015;22:1033-42. [PMID: 26081198 DOI: 10.1111/jvh.12430] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
43 Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827-838. [PMID: 29377196 DOI: 10.1002/hep.29811] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 29.7] [Reference Citation Analysis]
44 Gallo A, Miele M, Badami E, Conaldi PG. Molecular and cellular interplay in virus-induced tumors in solid organ recipients. Cellular Immunology 2019;343:103770. [DOI: 10.1016/j.cellimm.2018.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Salam RA, Nabil B, Saber M, AbdelWahab HA, Saber T. Prevalence of Hepatitis C Virus Seropositivity and Its Impact on Coronary Artery Disease among Egyptian Patients Referred for Coronary Angiography. Cardiol Res Pract 2016;2016:1623197. [PMID: 27882261 DOI: 10.1155/2016/1623197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
46 Tang B, Zhu G, Chen C, Zheng S, Pu Y, Xu Y, Huang H, Wang G, Huang D, Liu Y, Zhang X. Hepatitis C Virus RNA Transcript Associates with Prognosis in Non-human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma. Laryngoscope 2021;131:1774-81. [PMID: 33592124 DOI: 10.1002/lary.29422] [Reference Citation Analysis]
47 LaHue SC, Torres D, Rosendale N, Singh V. Stroke Characteristics, Risk Factors, and Outcomes in Transgender Adults: A Case Series. Neurologist 2019;24:66-70. [PMID: 30817494 DOI: 10.1097/NRL.0000000000000226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017;1:439-452. [PMID: 29404471 DOI: 10.1002/hep4.1049] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
49 Lin CZ, Ou RW, Hu YH. Lentiviral-mediated microRNA-26b up-regulation inhibits proliferation and migration of hepatocellular carcinoma cells. Kaohsiung J Med Sci 2018;34:547-55. [PMID: 30309482 DOI: 10.1016/j.kjms.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
50 Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y. Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data. Infect Dis Ther 2019;8:285-99. [PMID: 30771220 DOI: 10.1007/s40121-019-0234-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145-1160. [PMID: 27640316 DOI: 10.1016/j.autrev.2016.09.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
52 Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol 2018;24:5297-311. [PMID: 30598575 DOI: 10.3748/wjg.v24.i47.5297] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
53 Uruha A, Noguchi S, Hayashi YK, Tsuburaya RS, Yonekawa T, Nonaka I, Nishino I. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology 2016;86:211-7. [PMID: 26683644 DOI: 10.1212/WNL.0000000000002291] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 6.2] [Reference Citation Analysis]
54 Ishizaka N, Ishizaka Y, Yamkado M. Atherosclerosis as a possible extrahepatic manifestation of chronic hepatitis C virus infection. Clin Med Insights Cardiol. 2014;8:1-5. [PMID: 25452704 DOI: 10.4137/cmc.s17069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
55 Fabrizi F, Donato FM, Messa P. Hepatitis C and Its Metabolic Complications in Kidney Disease. Ann Hepatol. 2017;16:851-861. [PMID: 29055921 DOI: 10.5604/01.3001.0010.5275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
56 Molina-sánchez P, Lujambio A. Experimental Models for Preclinical Research in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 333-58. [DOI: 10.1007/978-3-030-21540-8_16] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol 2021;27:1267-82. [PMID: 33833481 DOI: 10.3748/wjg.v27.i13.1267] [Reference Citation Analysis]
58 Hashimoto Y, Tada M, Iida M, Nagase S, Hata T, Watari A, Okada Y, Doi T, Fukasawa M, Yagi K, Kondoh M. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model. Biochem Biophys Res Commun 2016;477:91-5. [PMID: 27286708 DOI: 10.1016/j.bbrc.2016.06.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
59 Abd-Elsalam S, Abo-Amer YE, El-Abgeegy M, Elshweikh SA, Elsergany HF, Ahmed R, Elkadeem M, Hawash N, Soliman S, Badawi R, Elguindy AMA, Soliman MY, Mohmed AA, Mansour L. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience. Medicine (Baltimore) 2020;99:e21972. [PMID: 33080669 DOI: 10.1097/MD.0000000000021972] [Reference Citation Analysis]
60 Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115-125. [PMID: 27508181 DOI: 10.2147/jhc.s44381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.9] [Reference Citation Analysis]
61 Olubamwo O, Aregbesola A, Miettola J, Kauhanen J, Tuomainen T. Hepatitis C and risk of coronary atherosclerosis – A systematic review. Public Health 2016;138:12-25. [DOI: 10.1016/j.puhe.2016.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
62 Verbeek TA, Stine JG, Saner FH, Bezinover D. Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management. Transplant Direct 2018;4:e403. [PMID: 30534594 DOI: 10.1097/TXD.0000000000000843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 4.3] [Reference Citation Analysis]
63 Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, Rinaldi L, Sellitto A, Giordano M, Marrone A. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015;21:2269-2280. [PMID: 25741133 DOI: 10.3748/wjg.v21.i8.2269] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 51] [Article Influence: 13.2] [Reference Citation Analysis]
64 Barré T, Rojas Rojas T, Lacombe K, Protopopescu C, Poizot-Martin I, Nishimwe ML, Zucman D, Esterle L, Billaud E, Aumaitre H, Bouchaud O, Rey D, Piroth L, Salmon-Ceron D, Wittkop L, Sogni P, Carrieri MP, Serfaty L, Marcellin F. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Rev Anti Infect Ther 2021;19:1147-56. [PMID: 33538612 DOI: 10.1080/14787210.2021.1884545] [Reference Citation Analysis]
65 Peschel G, Grimm J, Buechler C, Gunckel M, Pollinger K, Aschenbrenner E, Kammerer S, Jung EM, Haimerl M, Werner J, Müller M, Weigand K. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapy. Clin Hemorheol Microcirc 2021. [PMID: 34120896 DOI: 10.3233/CH-211193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Toma L, Dodot M, Zgura A, Bacalbasa N, Silaghi A, Simu R, Isac T, Mercan-Stanciu A. Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus. Clin Exp Med 2021. [PMID: 34254197 DOI: 10.1007/s10238-021-00743-7] [Reference Citation Analysis]
67 Choi HG, Soh JS, Lim JS, Sim SY, Lee SW. Association between dementia and hepatitis B and C virus infection. Medicine (Baltimore) 2021;100:e26476. [PMID: 34398003 DOI: 10.1097/MD.0000000000026476] [Reference Citation Analysis]
68 Donnally CJ 3rd, Patel PD, Canseco JA, Shenoy K, Divi SN, Goz V, Arain AR, Vaccaro AR. Hepatitis C Virus Infection as a Predictor of Complications and Increased Costs Following Primary Lumbar Fusion Surgery. Spine (Phila Pa 1976) 2020;45:E1020-5. [PMID: 32706565 DOI: 10.1097/BRS.0000000000003481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Ambrosino P, Tarantino L, Criscuolo L, Nasto A, Celentano A, Di Minno MN. The risk of venous thromboembolism in patients with hepatitis C: A systematic review and meta-analysis. Thromb Haemost 2017;116:958-66. [DOI: 10.1160/th16-03-0185] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 4.8] [Reference Citation Analysis]
70 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 90] [Article Influence: 28.8] [Reference Citation Analysis]
71 Bedimo R, Cutrell J, Zhang S, Drechsler H, Gao A, Brown G, Farukhi I, Castanon R, Tebas P, Maalouf NM. Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease. AIDS 2016;30:601-8. [PMID: 26558726 DOI: 10.1097/QAD.0000000000000952] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
72 Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Oncogenic Signaling Induced by HCV Infection. Viruses 2018;10:E538. [PMID: 30279347 DOI: 10.3390/v10100538] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
73 Revuelto Artigas T, Betriu Bars À, Zaragoza Velasco N, Gómez Arbones X, Vidal Ballester T, Piñol Felis C, Reñé Espinet JM. Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus. Gastroenterol Hepatol 2019;42:362-71. [PMID: 30952463 DOI: 10.1016/j.gastrohep.2019.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Boglione L, Lupia T, Cariti G, Di Perri G. Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders. J Infect Chemother 2020;26:18-22. [PMID: 31301972 DOI: 10.1016/j.jiac.2019.06.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Ilyas SZ, Tabassum R, Hamed H, Rehman SU, Qadri I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunol 2017;30:633-41. [PMID: 28953449 DOI: 10.1089/vim.2017.0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
76 Chen WC, Tseng CK, Chen YH, Lin CK, Hsu SH, Wang SN, Lee JC. HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway. PLoS One. 2015;10:e0133264. [PMID: 26231035 DOI: 10.1371/journal.pone.0133264] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
77 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
78 Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C; CARDIAC study group. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis 2018;18:518. [PMID: 30326844 DOI: 10.1186/s12879-018-3426-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
79 Winslow DL. Hepatitis C virus infection and cardiac dysfunction in women. AIDS 2021;35:1689-90. [PMID: 34270491 DOI: 10.1097/QAD.0000000000002938] [Reference Citation Analysis]
80 Foka P, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, Varaklioti A, Mamalaki A, Georgopoulou U. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency. Virulence 2016;7:679-90. [PMID: 27058404 DOI: 10.1080/21505594.2016.1175700] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
81 Yu S, Su C, Luo X. Impact of infection on transplantation tolerance. Immunol Rev 2019;292:243-63. [PMID: 31538351 DOI: 10.1111/imr.12803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Husa P, Snopkova S, Zavrelova J, Zlamal F, Svacinka R, Husa P. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021;165:146-51. [PMID: 33928944 DOI: 10.5507/bp.2021.023] [Reference Citation Analysis]
83 Anthony DD, Sulkowski MS, Smeaton LM, Damjanovska S, Shive CL, Kowal CM, Cohen DE, Bhattacharya D, Alston-Smith BL, Balagopal A, Wyles DL. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. J Infect Dis 2020;222:1334-44. [PMID: 32406487 DOI: 10.1093/infdis/jiaa254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
85 Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clin Infect Dis 2018;66:1742-50. [PMID: 29272349 DOI: 10.1093/cid/cix1106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
86 Hassan EA, Abd El-Rehim AS, Seifeldein GS, Shehata GA. Minimal hepatic encephalopathy in patients with liver cirrhosis: magnetic resonance spectroscopic brain findings versus neuropsychological changes. Arab J Gastroenterol 2014;15:108-13. [PMID: 25459346 DOI: 10.1016/j.ajg.2014.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
87 Ogdie A, Pang WG, Forde KA, Samir BD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy RK, Schumacher RH, Lo Re V 3rd. Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord 2015;16:93. [PMID: 25896674 DOI: 10.1186/s12891-015-0552-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
88 Mathew S, Faheem M, Ibrahim SM, Iqbal W, Rauff B, Fatima K, Qadri I. Hepatitis C virus and neurological damage. World J Hepatol. 2016;8:545-556. [PMID: 27134702 DOI: 10.4254/wjh.v8.i12.545] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
89 Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol 2018;24:4617-21. [PMID: 30416309 DOI: 10.3748/wjg.v24.i41.4617] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
90 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Gómez ME, Gentile EA, Martini MF, Cuestas ML, Mathet VL, Moltrasio GY, Moglioni AG. Synthesis of New Indanyl Nucleoside Analogues and their Biological Evaluation on Hepatitis C Virus (HCV) Replicon. Molecules 2019;24:E990. [PMID: 30862130 DOI: 10.3390/molecules24050990] [Reference Citation Analysis]
92 Jiang C, Long J, Liu B, Xie X, Kuang M. Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells. Biomed Res Int 2015;2015:572738. [PMID: 26078955 DOI: 10.1155/2015/572738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
93 Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol. 2014;20:3410-3417. [PMID: 24707124 DOI: 10.3748/wjg.v20.i13.3410] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 95] [Article Influence: 17.8] [Reference Citation Analysis]
94 Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M, Nasto A, Di Minno MN. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017;117:139-148. [PMID: 27761574 DOI: 10.1160/th16-06-0450] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 14.4] [Reference Citation Analysis]
95 Liu Y, Chen L, Zou Z, Zhu B, Hu Z, Zeng P, Wu L, Xiong J. Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells. J Med Virol 2016;88:1596-603. [PMID: 26895737 DOI: 10.1002/jmv.24504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
96 Leal VNC, Reis EC, Pontillo A. Inflammasome in HIV infection: Lights and shadows. Mol Immunol 2020;118:9-18. [PMID: 31835091 DOI: 10.1016/j.molimm.2019.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Al-Anazi MR, Matou-Nasri S, Abdo AA, Sanai FM, Alkahtani S, Alarifi S, Alkahtane AA, Al-Yahya H, Ali D, Alessia MS, Alshahrani B, Al-Ahdal MN, Al-Qahtani AA. Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. J Immunol Res 2017;2017:1590653. [PMID: 28127569 DOI: 10.1155/2017/1590653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
98 Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, Cheung R, Wong RJ. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci 2015;60:2813-24. [DOI: 10.1007/s10620-015-3760-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
99 Kim HM, Lee YH, Han K, Lee BW, Kang ES, Kim J, Cha BS. Impact of diabetes mellitus and chronic liver disease on the incidence of dementia and all-cause mortality among patients with dementia. Medicine (Baltimore) 2017;96:e8753. [PMID: 29381970 DOI: 10.1097/MD.0000000000008753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
100 Rogal SS, Bielefeldt K, Wasan AD, Szigethy E, Lotrich F, DiMartini AF. Fibromyalgia symptoms and cirrhosis. Dig Dis Sci 2015;60:1482-9. [PMID: 25433921 DOI: 10.1007/s10620-014-3453-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
101 Huynh T, Zhang J, Hu KQ. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. J Clin Transl Hepatol 2018;6:258-63. [PMID: 30271737 DOI: 10.14218/JCTH.2018.00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
102 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
103 Chudnovets A, Liu J, Narasimhan H, Liu Y, Burd I. Role of Inflammation in Virus Pathogenesis during Pregnancy. J Virol 2020;95:e01381-19. [PMID: 33115865 DOI: 10.1128/JVI.01381-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
104 Revuelto Artigas T, Zaragoza Velasco N, Gómez Arbones X, Vidal Ballester T, Piñol Felis C, Reñe Espinet JM, Betriu Bars A. Chronic hepatitis C infection: An independent risk factor for subclinical atheromatosis. Rev Clin Esp (Barc) 2019;219:293-302. [PMID: 30773286 DOI: 10.1016/j.rce.2018.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
105 Chan ST, Lee J, Narula M, Ou JJ. Suppression of Host Innate Immune Response by Hepatitis C Virus via Induction of Autophagic Degradation of TRAF6. J Virol. 2016;90:10928-10935. [PMID: 27681126 DOI: 10.1128/jvi.01365-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 4.6] [Reference Citation Analysis]
106 Adinolfi LE, Nevola R, Rinaldi L, Romano C, Giordano M. Chronic Hepatitis C Virus Infection and Depression. Clin Liver Dis 2017;21:517-34. [PMID: 28689590 DOI: 10.1016/j.cld.2017.03.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
107 Flores-Contreras L, Sandoval-Rodríguez AS, Mena-Enriquez MG, Lucano-Landeros S, Arellano-Olivera I, Alvarez-Álvarez A, Sanchez-Parada MG, Armendáriz-Borunda J. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol 2014;14:131. [PMID: 25064094 DOI: 10.1186/1471-230X-14-131] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 6.4] [Reference Citation Analysis]
108 Nielsen NS, Jespersen S, Gaardbo JC, Arnbjerg CJ, Clausen MR, Kjær M, Gerstoft J, Ballegaard V, Ostrowski SR, Nielsen SD. Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection. Int J Mol Sci 2017;18:E1016. [PMID: 28481325 DOI: 10.3390/ijms18051016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
109 Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, Tanaka J. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. J Viral Hepat 2021;28:1293-303. [PMID: 34185932 DOI: 10.1111/jvh.13562] [Reference Citation Analysis]
110 Rebbani K, Tsukiyama-Kohara K. HCV-Induced Oxidative Stress: Battlefield-Winning Strategy. Oxid Med Cell Longev. 2016;2016:7425628. [PMID: 27293514 DOI: 10.1155/2016/7425628] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
111 Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24:469-482. [PMID: 25801890 DOI: 10.1177/0961203314556140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
112 Uslu AU, Aydin B, Balta S, Yonem O, Uncu T, Seven D. The effect of standard therapy on mean platelet volume in patients with chronic hepatitis C. Prz Gastroenterol 2016;11:200-5. [PMID: 27713783 DOI: 10.5114/pg.2016.57942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
113 Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. Journal of Hepatology 2018;68:904-11. [DOI: 10.1016/j.jhep.2017.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]